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Abstract 
The fusion of the anaplastic lymphoma receptor 
tyrosine kinase (ALK) gene in myeloid malignancies 
is extremely rare. The RANBP2-ALK fusion of 
inv(2)(p23q13)/t(2;2)(p23;q13) combined with 
monosomy 7 has been reported in a few patients 
diagnosed with acute myelomonocytic leukemia or 
juvenile myelomonocytic leukemia. 
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Identity 
The inv(2)(p23q13) is an example of two variants 
involving ALK gene at 2p23 and RANBP2 gene at 
2q13, inv(2) and t(2;2). The RANBP2/ALK fusion 
combined with monosomy 7 is associated with 
myeloid malignancies. This chromosomal 
rearrangement has also been observed in 
inflammatory myofibroblastic tumors (IMT). 
Disease 
Myeloid lineage: acute myelomonocytic leukemia, 
juvenile myelomonocytic leukemia 
Phenotype/cell stem origin 
Three cases of acute myelomonocytic leukemia 
(AML-M4), two cases of juvenile myelomonocytic 
leukemia (JMML). 
Epidemiology 
Five cases reported to date: 3M/2F; age 3.5-75 years 
(median 16 years). 
Clinics 
The five patients with inv(2)(p23q13) or 
t(2;2)(p23;q13) were two women (31, 75 years) and 
one 16 year-old male with acute myelomonocytic 
leukemia, and two boys (3.5, 8 years) with juvenile 
myelomonocytic leukemia. 
The median WBC was 85.3 x 109/L (range, 55.6-
143.6 x 109/L) and median monocyte count was 27 x 
109/L (range, 20-55 x 109/L). 
inv(2)(p23q13) G-banding. Courtesy Eul-Ju Seo.Clinics and pathology
inv(2)(p23q13) RANBP2/ALK Seo EJ 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2015; 19(12) 709 
 
 
FISH with ALK break apart probe. A split signal indicates pericentric inversion in the inv(2)(p23q13), showing ALK gene 
rearrangement. Courtesy Eul-Ju Seo. 
 
Cytology 
Bone marrow: marked hypercellularity, granulocytic 
hyperplasia with leukemic blasts of myelomonocytic 
morphology. 
Immunohistochemistry for ALK protein: strong 
staining of the nuclear membrane in leukemic cells. 
Prognosis 
In four cases, early relapse after 1 to 6 months; in 
two cases, early death after 2 and 14 months. Two 
pediatric patients were alive at 6 and 8 years after 
stem cell transplantation. 
Cytogenetics 
Cytogenetics morphological 
Four out of five cases showed inv(2)(p23q13), and 
one case of JMML had t(2;2)(p23;q13). 
Interestingly, the monosomy 7 abnormality was 
observed in all cases, while it has not yet been 
reported in IMT cases. 
Additional anomalies 
Monosomy 7 (100%). 
 
Genes involved and 
proteins 
ELL 
Location 
2p23 
Protein 
1620 amino acids; 177 kDa; receptor tyrosine kinase. 
RANBP2 
Location 
2q12.3 
Protein 
3224 amino acids; 358 kDa; large RAN-binding 
protein that immunolocalizes to the nuclear pore 
complex; E3 SUMO-protein ligase which facilitates 
SUMO1 and SUMO2 conjugation by UBE2I. 
Involved in facilitation of protein import and export, 
sumoylation of protein cargoes, intracellular 
trafficking, and energy maintenance. 
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Result of the chromosomal 
anomaly 
Hybrid gene 
Description 
5' RANBP2 - 3' ALK. 
Transcript 
In-frame fusion transcript between RANBP2 exon 
18 and ALK exon 20 in all cases. 
Fusion protein 
Description 
1430-amino acid RANBP2-ALK fusion protein; The 
first 867 N-term amino acids of RANBP2 fused to 
the 563 C-term amino acids of ALK (i.e. the leucine-
rich domain, including the leucine zipper, of 
RANBP2 and the entire cytoplasmic portion of ALK 
with the tyrosine kinase domain). 
Expression / Localisation 
Nuclear membrane. 
 
 
Oncogenesis 
RANBP2 protein contains an N-terminal 700-
residue leucine-rich region predicted to mediate 
homo-oligomerization of the RANBP2-ALK 
oncoprotein, leading to the activation of the ALK 
kinase catalytic function. 
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